PLEASANTON, Calif., FRAMINGHAM, Mass. and SYDNEY, July 29 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR - News), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, and HeartWare International, Inc. (Nasdaq: HTWR - News; ASX: HIN - News), which develops and manufactures miniaturized implantable heart pumps, announced today that the United States Federal Trade Commission ("FTC") has informed them that the FTC will file a complaint in U.S. Federal District Court to challenge Thoratec's proposed acquisition of HeartWare International.
